Kodiak Sciences Jumps After DAYBREAK: What the Wet AMD Data Show and What Still Has to Happen

Kodiak Sciences (NASDAQ: KOD) reported positive topline results from its DAYBREAK Phase 3 wet AMD study on September 28, 2026. Both Zenkuda (tarcocimab tedromer) and tabirafusp-ted met their primary endpoints, and the company plans to file a Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026. Shares were reported at roughly $55–60 in premarket trading, up about 70–87% from Friday's close of $32.35. Kodiak has no commercial product, no revenue, and about $126 million in cash as of the second quarter, so the data resolve a major clinical question while leaving the financing and approval questions open.

What Did DAYBREAK Show?

DAYBREAK tested two Kodiak candidates against the aflibercept control in patients with wet age-related macular degeneration (wAMD), and both hit their primary endpoints. For Zenkuda, the primary endpoint carried a p-value of 0.0007, with the company reporting meaningful vision gains and rapid, sustained drying of the retina. Fifty-four percent of Zenkuda patients reached a six-month dosing interval under a strict treat-to-dryness retreatment standard designed to mirror real-world practice.

Safety looked clean in the topline. Intraocular inflammation was 0%, and cataract adverse events were 0.5% for Zenkuda versus 0.9% for aflibercept. The second candidate, tabirafusp-ted (KSI-501), is an anti-IL-6 and VEGF bispecific. It met its visual acuity primary endpoint with p=0.0036 and a key anatomical secondary endpoint with p<0.0001.

These are topline figures from a company press release. Full data, including the comparator arm's dosing frequency and the distribution of visual acuity outcomes, will determine how the results are read against existing therapies.

Why Does the Six-Month Interval Matter?

Wet AMD patients typically receive injections into the eye every one to three months, and the treatment burden is one of the largest commercial and clinical pain points in retina care. Kodiak's Antibody Biopolymer Conjugate (ABC) platform is built to extend how long a biologic stays active in the eye, so fewer injections can maintain disease control. A reported 54% rate of six-month intervals is the number that speaks to that thesis.

The qualifier is the retreatment standard. Kodiak describes it as strict, treat-to-dryness, and reflective of real-world practice, which makes the figure more meaningful if it holds up under regulatory review. How the comparison against aflibercept is framed, and whether physicians in routine practice will extend intervals as aggressively as a trial protocol allows, are questions the topline release cannot answer.

What Comes Next: BLA Timing and the Pipeline

Kodiak intends to submit a multi-indication BLA for Zenkuda in the fourth quarter of 2026, covering wAMD, diabetic retinopathy and retinal vein occlusion. The company says the filing rests on five positive Phase 3 studies. A single application spanning three indications is an ambitious package, and FDA review timelines, information requests, and manufacturing inspections all sit between submission and any approval decision.

The pipeline also has near-term milestones. KSI-501 will move into accelerated development for diabetic macular edema, with the ALTO Phase 3 study already enrolling. KSI-101, aimed at macular edema secondary to inflammation (MESI), has completed enrollment in the first pivotal cohort of its PEAK Phase 3 study, with topline data expected in December 2026. That gives investors a second dated data event within roughly three months.

Is the Balance Sheet a Problem?

Cash stood at approximately $126 million at the end of the second quarter of 2026, and management has said this supports operations into 2027. Against that, the company is preparing a BLA, running multiple Phase 3 programs, and would need to build commercial infrastructure if Zenkuda is approved. At Friday's close of $32.35, market capitalization was about $2.03 billion; at the reported premarket range, it would be roughly $3.5–3.8 billion on the same share count, which is an estimate from the reported figures.

Companies in this position commonly raise equity after strong data, when the share price is highest. Kodiak has not announced an offering, and the exact path could also include a partnership or a royalty or debt arrangement. Whichever route it takes, the runway into 2027 means financing is a question for the coming months, not a distant one.

How Volatile Is This Stock?

KOD carries a beta of about 2.2, and its 52-week range of $10.94 to $47.84 shows how far it has moved on clinical news alone. The premarket price now sits above the prior 52-week high. Analyst consensus leans Strong Buy to Moderate Buy, with average price targets in the $56–70 range, and some firms had raised targets before this readout. Targets published before the data may be revised, so the current consensus is likely to shift over the coming days.

Trading around a binary event like this tends to produce large intraday swings. Premarket prices reflect thin liquidity, and the opening auction can land well away from them in either direction.

Who Runs the Company?

Victor Perlroth, M.D., co-founded Kodiak and has served as chairman and CEO since 2009, so the ABC platform and the retina-focused strategy reflect a single leader's long-running bet. John Borgeson is the chief financial officer. Dolly Chang is chief scientific officer, and Pablo Velazquez-Martin is chief medical officer. The board includes Felix Baker of Baker Brothers, Charles Bancroft and Bassil Dahiyat.

FAQ

Why is Kodiak Sciences stock up today?
KOD rose in premarket trading on September 28, 2026 after the company announced that its DAYBREAK Phase 3 wet AMD study met its primary endpoints for both Zenkuda and tabirafusp-ted. Reported premarket prices were around $55–60, versus a Friday close of $32.35.

What is Zenkuda?
Zenkuda (tarcocimab tedromer) is Kodiak's anti-VEGF antibody biopolymer conjugate, designed to stay active in the eye longer so patients need fewer injections. In DAYBREAK, 54% of patients reached a six-month dosing interval under a strict treat-to-dryness standard.

When will Kodiak file for FDA approval?
The company plans to submit a multi-indication BLA for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion.

Does Kodiak have enough cash?
Kodiak held about $126 million at the end of the second quarter of 2026, and management says that funds operations into 2027. The company has not announced a financing.

What is the next catalyst after DAYBREAK?
Topline data from the first pivotal cohort of the KSI-101 PEAK Phase 3 study are expected in December 2026, alongside the Zenkuda BLA submission in the fourth quarter.

Trade US stocks/Hong Kong stocks/Taiwan stocks ,etc Online Global Trending Stocks

Start Trading Now >